Trius Therapeutics (TSRX) Files $86.25M IPO
Trius Therapeutics, Inc. (NASDAQ: TSRX) filed a registration statement with the SEC for an initial public offering of its common stock. The proposed maximum aggregate offering price is $86.25 million. The company plans to list on the NASDAQ under the stock symbol "TSRX."
The offering is being made through Credit Suisse, Piper Jaffray, Canaccord Adams, and JMP Securities.
Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. They are preparing to initiate Phase 3 clinical trials for torezolid phosphate, an IV and orally administered second generation oxazolidinone, for the treatment of serious gram-positive bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus, or MRSA.
Stocks Mentioned
Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
